Abstract: The present disclosure is related to methods and compositions for treating or preventing kidney injury or failure, comprising administering an endothelin B (ETB) receptor agonist and/or an ?2 adrenergic agent.

Abstract: A pharmaceutical formulation for treatment of cerebral stroke includes an endothelin-B receptor analog in a dosing range of 0.00001 mg/kg?1 mg/kg, and a drug in a dosing range of 0.0015 g/kg-5 g/kg, wherein endothelin-B receptor analog includes, but not limited to sovateltide, BQ-3020, [Ala1,3,11,15]-endothelin, sarafotoxin S6c, endothelin-3, and the drug includes, but not limited to mannitol and citicoline.

Abstract: The aspects of the disclosed embodiments relate to a composition using an endothelin B receptor agonist, such as sovateltide (N-Succinyl-[Glu9, Ala11,15] endothelin 1, IRL-1620), for increasing proliferation and protecting the existing neuroepithelium of cochlear and vestibular cells located within the otic capsule. The composition is placed transtympanically, via a cochleostomy, or systemically through an intravenous or intramuscular form. A method for treating sensorineural hearing loss and vestibular symptoms caused by degeneration of inner ear cells using a compound that includes endothelin analogs by the mechanism of neuroprotection and neurogenesis of cochleovestibular hair cells and synapses.

Abstract: The aspects of the disclosed embodiments relate to compositions and methods for treating wounds and or promoting wound healing and mammalian nerve regeneration of a damaged nerve. In addition, the invention relates to the application of the therapeutic amount of an endothelin-B receptor agonist. Specifically, this application is directed to a method of using IRL-1620 (sovateltide) for treating dermal or cutaneous wounds and damaged cranial or peripheral nerves. The composition may include endothelin-B receptor agonists, which may include peptides such as sovateltide (IRL-1620). Delivery systems, including gels, sponges, gauzes, and meshes incorporating the agent for topical application, are also described.

Abstract: A pharmaceutical composition for treating acute respiratory distress syndrome (ARDS), multiple end organ failure and survival in serious and life-threatening condition in patients with coronavirus disease 2019 (COVID-19) including (a) centhaquine; (b) antiviral therapies for SARS-CoV-2 infection (remdesivir, ivermectin, chloroquine, hydroxychloroquine, azythromicyn, tenofovir, emtricitabine, ritonavir, lopinavir, ASC09, favipiravir, danoprevir, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), recombinant human angotensin-converting enzyme 2 (rhACE2), xiyanping, alpha-interferon, fludase (DAS181), eicosapentaenoic acid free fatty acid (EPA-FFA), nitric oxide, PUL-042, Pam2CSK4 acetate, agonists of TLR2 TLR6, and TLR9), convalescent plasma, stem cells or their exosomes, immunomodulation and cytokine-targeted therapies (itolizumab, tocilizumab, sarilumab, acalabrutinib, piclidenoson, tradipitant, CD24Fc, emapalumab, anakinra, TJ003234, BLD-2660, blood purification systems, Sp

Abstract: Methods of treating diseases and conditions wherein an improvement in cardiac output, organ perfusion, or tissue oxygenation are disclosed. The methods include treatments of diseases and conditions, such as hypovolemic shock, with an a2 adrenergic agent, like centhaquin and centhaquin citrate. The method utilizes an a2 adrenergic agent administered at low doses with a low volume of resuscitation fluid. Purified centhaquin and centhaquin citrate also are disclosed.